2 directors reappointedName hiddenVisible after signing in and PHARMACIE VERBORG-PONCELET (managing director) · Hidden nameVisible after signing in acts as permanent representative · General meeting of 31-03-2017 · Gazette deed
Company renamed to Novil'PharmaPHARMACIE VERBORG-PONCELET (chair of the board and managing director) and Name after signing inVisible after signing in (director) reappointed · Name hiddenVisible after signing in appointed as director · Hidden nameVisible after signing in acts as permanent representative · General meeting of 25-01-2013 · Gazette deed
“La société a pour objet toutes opérations se rapportant directement ou indirectement aux produits…” (deed in French)From the articles, 5 activitiesNo NACE code in the KBO
NOVIL'PHARMA had an average of 0.8 full-time equivalents in financial year 2018, according to the filed annual accounts.Financials
What is the turnover of NOVIL'PHARMA?
The turnover in financial year 2018 is ≈ €690,000. This figure is estimated from the gross margin of €288,869 and 2,135 comparable companies of the same size. It probably lies between €410,000 and €1.2m. It is a rough estimate.
Is NOVIL'PHARMA profitable?
In financial year 2018, NOVIL'PHARMA made a profit of €183,386.
Where can I find the annual accounts of NOVIL'PHARMA?
NOVIL'PHARMA filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2018.